Parkinson’s Disease Drugs

Parkinson’s disease drugs encompass a comprehensive therapeutic group aimed at alleviating motor and non-motor symptoms caused by progressive dopaminergic neuron degeneration in the substantia nigra. Core treatments include levodopa, the metabolic precursor of dopamine, administered with peripheral decarboxylase inhibitors to enhance central bioavailability. Dopamine agonists such as pramipexole, ropinirole, and rotigotine directly stimulate dopamine receptors, offering longer-lasting symptom control. MAO-B inhibitors and COMT inhibitors prolong endogenous and exogenous dopamine activity, reducing “off” periods and motor fluctuations. Additional agents include anticholinergics for tremor-predominant disease, amantadine for dyskinesia control, and adenosine A2A antagonists for motor improvement. These therapies significantly improve movement, gait, rigidity, and daily functioning. However, long-term treatment requires careful adjustment to manage complications such as dyskinesias, impulse-control disorders, hallucinations, and orthostatic hypotension. Parkinson’s disease drug development continues to evolve, with a growing focus on neuroprotective strategies and disease-modifying interventions.